ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
ƾ֤GLP-1R×÷ÓÃʱ¼ä£¬GLP-1R¼¤¶¯¼Á¿ÉÒÔ·ÖΪ¶ÌЧºÍ³¤Ð§Á½´óÀà¡£
Based on their ability to activate GLP-1 receptor£¬GLP-1 receptor agonists can be classified as short- acting and long-acting GLP-1R agonist.
¶ÌЧGLP-1R ¼¤¶¯¼Á£¬ÐèÒªÖðÈÕÒ»´Î»òÕßÖðÈÕÁ½´Î¸øÒ©¡£
Short-acting GLP-1R agonists are required to give either a once daily (QD) or twice-daily£¨BID£©dosing.
Èç°¬ÈûÄÇëĺÍÀûÎ÷Àëĵȣ¬³¤Ð§GLP-1R¼¤¶¯¼ÁÊǶԻ¯ºÏÎï·Ö×Ó¾ÙÐÐÁËһЩ½á¹¹ÐÞÊΣ¬ÕâÑù¿ÉÒÔÔöÇ¿Æä×÷ÓÃʱ¼ä£¬Í¬Ê±±£´æÆä×÷ÓÃÓÚGLP-1R µÄÄÜÁ¦.Èç¶ÅÀ³ëÄ¡¢°¢±ØÂ³ëĵȣ¬Ã¿ÖܸøÒ©Ò»´Î¼´¿É¡£
For example Exenatide and Lixisenatide, long acting GLP-1R agonists have undergone some structural modifications to enhance their duration of action while retaining their ability to act on the GLP-1 receptors. For example Albiglutide,Dulaglutide, once weekly.
¡¾Æ½Ì¨¡¿¡°GLP-1¡±ÐÂÒ©Ñз¢Ð§ÀÍÆ½Ì¨
¡¾ÊÓÆµ¡¿GLP-1 ×÷ÓûúÖÆ
¡¾ÊÓÆµ¡¿GLP-1s µÄÐÄÀí×÷ÓÃ
¡¾ÊÓÆµ¡¿ÒȸßѪÌÇËØÑùëÄ-1(GLP-1s) ÏÈÈÝ
¡¾ÐÂÎÅ¡¿GLP-1ÈÃ×¢Éä³ÔÒ©Ò²Äܼõ·Ê³ÉΪÏÖʵ